Ajinomoto Co., Inc. Acquires Forge Biologics

Asahi Kasei Medical Acquires Bionova Scientific

April 14, 2022

Biotechnology

Asahi Kasei Medical agreed to wholly acquire Bionova Scientific, a Fremont, California-based biopharmaceutical CDMO that provides process development and GMP-compliant manufacturing services for next-generation antibody drugs. The acquisition, executed through a U.S. subsidiary, expands Asahi Kasei Medical's bioprocess and CDMO capabilities to better serve biologics developers and accelerate growth of its bioprocess business; closing is subject to regulatory clearances.

Bayer AG Acquires Asklepios BioPharmaceutical (AskBio)

October 26, 2020

Biotechnology

Bayer AG agreed to acquire U.S.-headquartered Asklepios BioPharmaceutical (AskBio), adding AskBio's AAV-based gene therapy platform, IP and CDMO manufacturing capabilities to Bayer’s emerging cell and gene therapy unit. Bayer will pay $2.0 billion upfront plus up to $2.0 billion in potential milestone payments; existing minority shareholders TPG Capital and Vida Ventures supported the transaction.

Charles River Laboratories Acquires Vigene Biosciences

May 17, 2021

Biotechnology

Charles River Laboratories agreed to acquire Vigene Biosciences, a Rockville, Maryland-based gene therapy CDMO, for $292.5 million in cash plus up to $57.5 million in contingent payments. The acquisition expands Charles River's cell and gene therapy contract development and manufacturing capabilities—adding CGMP viral vector and plasmid DNA production—and is expected to close in early Q3 2021.

Agilent Technologies Acquires BIOVECTRA for $925M

July 22, 2024

Pharmaceuticals

Agilent Technologies has acquired BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO), for $925 million. The acquisition — a purchase from H.I.G. Capital — expands Agilent's CDMO capabilities across biologics, HPAPIs, pDNA/mRNA and LNP formulation, and integrates BIOVECTRA into Agilent's Diagnostics and Genomics Group.

Bristol Myers Squibb Acquires Forbius

August 24, 2020

Biotechnology

Bristol Myers Squibb entered into a definitive agreement to acquire Forbius, a clinical-stage protein engineering company, to obtain its isoform‑selective TGF‑beta 1 & 3 program including lead asset AVID200. The deal includes an upfront payment plus potential milestone payments; Forbius' non‑TGF‑beta assets will be transferred to a newly formed private company retained by Forbius' existing shareholders, and the parties expected to close in Q4 2020 subject to customary conditions.

Takeda Pharmaceutical Acquires PvP Biologics

February 26, 2020

Biotechnology

Takeda Pharmaceutical Company Limited exercised its option to acquire PvP Biologics, Inc. following positive Phase 1 proof-of-mechanism results for TAK-062 (Kuma062), an oral engineered glutenase for celiac disease. The deal includes a pre-negotiated upfront payment and up to $330 million in development and regulatory milestones and brings TAK-062 and TAK-101 into Takeda's gastroenterology pipeline.